CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article


Fig. 1. PP1 blocks SCF-stimulated MAPK activation. A, H526 cells incubated in serum-free medium overnight were either left untreated (NS), or stimulated with 100 ng/ml SCF or 20 ng/ml IGF-1 in the presence of DMSO vehicle or 10 µM PP1 and lysed in SDS sample buffer after 5 min. Duplicate samples were resolved by PAGE through a 10% gel, Western blotted, and stained with either an activation-specific or a pan-ERK antibody. SCF stimulation resulted in a 10-fold increase in MAPK activity (determined by densitometry), which was completely inhibited by PP1. IGF-1 resulted in a 2-fold increase in MAPK activity that was not affected by PP1. B, H526 cells were treated as above, lysed, and ERK 1 and 2 were immunoprecipitated with a pan-ERK antibody. The immunoprecipitate was incubated in the presence of myelin basic protein and {gamma}32P-ATP in triplicate and the labeled myelin basic protein was bound to phosphocellulose paper, was washed, and was quantitated by scintillation counting.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation